TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma-Reference-Cited by-同舟云学术

TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma

Published:2018-10-18 Issue:16 Volume:132 Page:1689-1694
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Guillerey Camille¹²^ORCID,Harjunpää Heidi²³,Carrié Nadège⁴,Kassem Sahar⁴,Teo Tricia¹²,Miles Kim¹,Krumeich Sophie¹,Weulersse Marianne⁴,Cuisinier Marine⁴,Stannard Kimberley¹,Yu Yuan¹,Minnie Simone A.⁵,Hill Geoffrey R.⁵,Dougall William C.¹,Avet-Loiseau Hervé⁴⁶,Teng Michele W. L.²³,Nakamura Kyohei¹^ORCID,Martinet Ludovic⁴⁶^ORCID,Smyth Mark J.¹²^ORCID

Affiliation:

1. Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute,

2. School of Medicine, The University of Queensland, and

3. Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia;

4. Cancer Research Center of Toulouse, INSERM UMR 1037, Toulouse, France;

5. Bone Marrow Transplantation Cancer Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia; and

6. Institut Universitaire du Cancer, Toulouse, France

Abstract

Key Points TIGIT expression is upregulated on CD8+ T cells during MM progression and is associated with impaired effector functions. TIGIT deficiency or blockade protects mice against MM and improves effector functions of myeloma patient CD8+ T cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/132/16/1689/1407068/blood825265.pdf

Reference19 articles.

1. Multiple myeloma;Kumar;Nat Rev Dis Primers,2017

2. Novel immunotherapies for multiple myeloma;D’Agostino;Curr Hematol Malig Rep,2017

3. The blockade of immune checkpoints in cancer immunotherapy;Pardoll;Nat Rev Cancer,2012

4. Combination cancer immunotherapies tailored to the tumour microenvironment;Smyth;Nat Rev Clin Oncol,2016

5. Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?;Rosenblatt;Blood,2017

Cited by 224 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to daratumumab in patients with multiple myeloma;Basic & Clinical Pharmacology & Toxicology;2024-08-26

2. Clinical response and pathway-specific correlates following TIGIT–LAG3 blockade in myeloma: the MyCheckpoint randomized clinical trial;Nature Cancer;2024-08-26

3. A comeback for checkpoint inhibition in multiple myeloma;Nature Cancer;2024-08-26

4. Target therapy of TIGIT; a novel approach of immunotherapy for the treatment of colorectal cancer;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-08-19

5. TIGIT expression on neoplastic cells is a poor prognostic factor for adult T-cell leukaemia/lymphoma;Pathology;2024-08